Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

Phase 1/2 Completed 7 enrolled Craig McDonald, MD Cardero Therapeutics, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

(-)-Epicatechin will be evaluated for the treatment of progressive muscle loss and impaired skeletal muscle function in Becker Muscular Dystrophy (BMD) patients.

Timeline

Start: 2013-05
Primary completion: 2018-09
Completion: 2018-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	(-)-Epicatechin	Unknown	100 mg	Oral

Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

Summary

Timeline

Drugs

Indications